TG Therapeutics, Inc. Forecasted to Earn FY2025 Earnings of $0.72 Per Share (NASDAQ:TGTX)

TG Therapeutics, Inc. (NASDAQ:TGTX) – Investment analysts at B. Riley cut their FY2025 earnings per share estimates for TG Therapeutics in a research note issued on Wednesday, May 1st. B. Riley analyst M. Mamtani now anticipates that the biopharmaceutical company will earn $0.72 per share for the year, down from their previous estimate of $0.78. B. Riley has a “Buy” rating and a $29.00 price target on the stock. The consensus estimate for TG Therapeutics’ current full-year earnings is ($0.10) per share. B. Riley also issued estimates for TG Therapeutics’ FY2026 earnings at $1.53 EPS, FY2027 earnings at $2.54 EPS and FY2028 earnings at $3.46 EPS.

Other analysts have also recently issued reports about the stock. HC Wainwright boosted their price objective on shares of TG Therapeutics from $45.00 to $49.00 and gave the company a “buy” rating in a research note on Thursday. StockNews.com lowered TG Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, February 24th. The Goldman Sachs Group raised their price objective on TG Therapeutics from $12.00 to $13.00 and gave the stock a “neutral” rating in a report on Thursday, February 29th. LADENBURG THALM/SH SH increased their target price on shares of TG Therapeutics from $39.00 to $40.00 and gave the stock a “buy” rating in a research report on Thursday. Finally, JPMorgan Chase & Co. reaffirmed an “overweight” rating and set a $25.00 price target on shares of TG Therapeutics in a research report on Thursday, April 18th. Two equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $29.83.

TG Therapeutics Stock Performance

Shares of TGTX stock opened at $16.19 on Friday. The company has a debt-to-equity ratio of 0.62, a quick ratio of 5.18 and a current ratio of 5.92. The firm has a market capitalization of $2.50 billion, a price-to-earnings ratio of 71.30 and a beta of 2.33. TG Therapeutics has a one year low of $6.46 and a one year high of $35.67. The company has a 50 day moving average price of $15.19 and a 200 day moving average price of $14.34.

TG Therapeutics (NASDAQ:TGTX) last posted its quarterly earnings data on Wednesday, May 1st. The biopharmaceutical company reported ($0.07) EPS for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.02). TG Therapeutics had a net margin of 14.24% and a return on equity of 33.79%. The company had revenue of $63.47 million for the quarter, compared to analyst estimates of $54.60 million. During the same period in the prior year, the company earned ($0.28) EPS. The company’s revenue was up 713.5% compared to the same quarter last year.

Institutional Trading of TG Therapeutics

Several large investors have recently modified their holdings of the business. Principal Financial Group Inc. boosted its holdings in TG Therapeutics by 3.9% in the first quarter. Principal Financial Group Inc. now owns 35,374 shares of the biopharmaceutical company’s stock valued at $538,000 after purchasing an additional 1,322 shares during the last quarter. Wealth Effects LLC boosted its stake in shares of TG Therapeutics by 17.9% during the 1st quarter. Wealth Effects LLC now owns 16,500 shares of the biopharmaceutical company’s stock valued at $251,000 after buying an additional 2,500 shares during the last quarter. Raymond James Financial Services Advisors Inc. grew its position in shares of TG Therapeutics by 4.4% during the first quarter. Raymond James Financial Services Advisors Inc. now owns 107,420 shares of the biopharmaceutical company’s stock worth $1,634,000 after buying an additional 4,548 shares in the last quarter. Hennion & Walsh Asset Management Inc. increased its stake in shares of TG Therapeutics by 16.9% in the first quarter. Hennion & Walsh Asset Management Inc. now owns 184,815 shares of the biopharmaceutical company’s stock worth $2,811,000 after buying an additional 26,761 shares during the last quarter. Finally, Los Angeles Capital Management LLC raised its holdings in TG Therapeutics by 55.8% in the first quarter. Los Angeles Capital Management LLC now owns 76,616 shares of the biopharmaceutical company’s stock valued at $1,165,000 after acquiring an additional 27,437 shares in the last quarter. 58.58% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, Director Laurence N. Charney sold 22,000 shares of TG Therapeutics stock in a transaction that occurred on Tuesday, March 12th. The shares were sold at an average price of $15.97, for a total transaction of $351,340.00. Following the sale, the director now owns 215,229 shares in the company, valued at $3,437,207.13. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 9.20% of the stock is owned by company insiders.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.